A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517322-26-00

Acronym

BG-60366-101

Enrollment

Registered

2025-05-12

Start date

2025-06-06

Completion date

Unknown

Last updated

2025-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR-Mutant Non-Small Cell Lung Cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026